quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Customer Data Platform Company Evaluation Report 2025: Salesforce, Oracle and Adobe Lead with AI-Driven Customer Insights, Real-Time Data Integration and Privacy-First Personalization

View original at finance.yahoo.com
Customer Data Platform Company Evaluation Report 2025: Salesforce, Oracle and Adobe Lead with AI-Driven Customer Insights, Real-Time Data Integration and Privacy-First Personalization Company Logo The Customer Data Platform Companies Quadrant offers an in-depth analysis of the global Customer Data Platform (CDP) market…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The global customer data platform market is projected to witness substantial growth between 2025 and 2030

    80% confidence

  • Over 100 companies were evaluated with the top 25 recognized as quadrant leaders in the Customer Data Platform market

    80% confidence

  • Third-party cookie deprecation is accelerating the shift toward first-party data via CDPs

    80% confidence

  • High setup and integration costs hinder CDP adoption among mid-sized companies

    80% confidence

  • Accurately resolving identities across devices and sessions remains technically complex

    80% confidence

  • A customer data platform (CDP) is a technology solution that consolidates customer data from various channels, systems, or sources into a unified, real-time customer profile

    80% confidence

  • Advancements in AI and machine learning are expected to further accelerate the expansion of the CDP market

    80% confidence

  • AI-powered CDPs can drive hyper-personalization

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com